ResMed
676 hedge funds and large institutions have $20.3B invested in ResMed in 2022 Q2 according to their latest regulatory filings, with 81 funds opening new positions, 215 increasing their positions, 260 reducing their positions, and 73 closing their positions.
181% more call options, than puts
Call options by funds: $54.3M | Put options by funds: $19.3M
50% more funds holding in top 10
Funds holding in top 10: 10 → 15 (+5)
11% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 73
0.69% less ownership
Funds ownership: 66.7% → 66.02% (-0.69%)
1% less funds holding
Funds holding: 682 → 676 (-6)
14% less capital invested
Capital invested by funds: $23.6B → $20.3B (-$3.32B)
17% less repeat investments, than reductions
Existing positions increased: 215 | Existing positions reduced: 260
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$273M |
| 2 |
Morgan Stanley
New York
|
+$122M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$114M |
| 4 |
Millennium Management
New York
|
+$59M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM Investment Management
Laguna Beach,
California
|
-$468M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$232M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$45.1M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$33.7M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$31.1M |
RMD Hedge Fund Activity: Q2 2022 in Review
676 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q2 2022, worth a combined $20.3B — down 14% from $23.6B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new RMD positions and 73 closed out — a net gain of 8 holders — while 215 added to existing stakes and 260 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $273M. The largest seller was WCM Investment Management, cutting an estimated $468M.
- 676 institutional investors held ResMed (RMD) as of Q2 2022, down from 682 in Q1 2022.
- Funds reported $20.3B of ResMed stock for Q2 2022, down 14% quarter-over-quarter.
- 81 funds opened new ResMed positions in Q2 2022 and 73 closed out, a net change of +8 holders.
- The largest ResMed buyer in Q2 2022 was Citadel Advisors, an estimated $273M added.
- The largest ResMed seller in Q2 2022 was WCM Investment Management, an estimated $468M sold.
Based on aggregated 13F filings for Q2 2022.